- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
King of Prussia Today
By the People, for the People
Acurx Pharmaceuticals Reports Earnings Results
The clinical-stage biopharmaceutical company exceeded earnings expectations for the quarter.
Mar. 13, 2026 at 7:38pm
Got story updates? Submit your updates here. ›
Acurx Pharmaceuticals (NASDAQ:ACXP) reported its latest quarterly earnings results, with the company posting a loss per share of $0.31, which was better than the consensus estimate of a $1.01 loss per share. Shares of the company traded down $1.61 on Friday, closing at $3.40.
Why it matters
Acurx Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing novel anti-infective therapies, with a focus on treating acute bacterial skin and skin structure infections (ABSSSI). The company's better-than-expected earnings results could signal progress in its drug development pipeline.
The details
For the quarter, Acurx Pharmaceuticals reported a loss per share of $0.31, exceeding the consensus estimate of a $1.01 loss per share. The company's shares traded down $1.61 on Friday, closing at $3.40. Acurx has a market capitalization of $8.67 million and its stock has traded in a range of $1.33 to $21.00 over the past 52 weeks.
- Acurx Pharmaceuticals reported its earnings results on Thursday, March 13, 2026.
- The company's shares traded on Friday, March 14, 2026.
The players
Acurx Pharmaceuticals
A clinical-stage biopharmaceutical company focused on developing novel anti-infective therapies, with a focus on treating acute bacterial skin and skin structure infections (ABSSSI).
The takeaway
Acurx Pharmaceuticals' better-than-expected earnings results suggest progress in the company's drug development pipeline, which could be a positive sign for investors as the company continues to advance its anti-infective therapies.
